Celularity to Present at H.C. Wainwright’s 26th Annual Global Investment Conference
Celularity (Nasdaq: CELU), a regenerative and cellular medicine company, announced its participation in H.C. Wainwright's 26th Annual Global Investment Conference. The event will take place at the Lotte New York Palace Hotel from September 9-11, 2024. Robert J. Hariri, M.D., Ph.D., Chairman, CEO, and founder of Celularity, is scheduled to present on Monday, September 9, 2024, at 12:30 p.m. ET.
In addition to the presentation, Celularity will engage in one-on-one investor meetings during the conference. Interested parties can contact H.C. Wainwright representatives or KCSA Strategic Communications to schedule meetings. A replay of the presentation will be available on Celularity's website for at least 90 days following the event.
Celularity (Nasdaq: CELU), una compagnia specializzata in medicina rigenerativa e cellulare, ha annunciato la sua partecipazione al 26° Annual Global Investment Conference di H.C. Wainwright. L'evento si svolgerà presso l'hotel Lotte New York Palace dal 9 all'11 settembre 2024. Robert J. Hariri, M.D., Ph.D., Presidente, CEO e fondatore di Celularity, è previsto che presenti lunedì 9 settembre 2024, alle 12:30 p.m. ET.
Oltre alla presentazione, Celularity parteciperà a incontri individuali con gli investitori durante la conferenza. Le parti interessate possono contattare i rappresentanti di H.C. Wainwright o KCSA Strategic Communications per pianificare gli incontri. Una registrazione della presentazione sarà disponibile sul sito web di Celularity per almeno 90 giorni dopo l'evento.
Celularity (Nasdaq: CELU), una empresa de medicina regenerativa y celular, anunció su participación en la 26ª Conferencia Global Anual de Inversión de H.C. Wainwright. El evento se llevará a cabo en el hotel Lotte New York Palace desde el 9 hasta el 11 de septiembre de 2024. Robert J. Hariri, M.D., Ph.D., Presidente, CEO y fundador de Celularity, está programado para presentar el lunes 9 de septiembre de 2024, a las 12:30 p.m. ET.
Además de la presentación, Celularity llevará a cabo reuniones individuales con inversores durante la conferencia. Las partes interesadas pueden contactar a los representantes de H.C. Wainwright o KCSA Strategic Communications para agendar reuniones. Una grabación de la presentación estará disponible en el sitio web de Celularity durante al menos 90 días después del evento.
Celularity (Nasdaq: CELU), 재생 및 세포 의학 기업,이 H.C. Wainwright 제26회 연례 글로벌 투자 회의에 참여한다고 발표했습니다. 이 행사는 2024년 9월 9일부터 11일까지 Lotte New York Palace Hotel에서 열릴 예정입니다. 로버트 J. 하리리, M.D., Ph.D., Celularity의 의장, CEO 및 창립자는 2024년 9월 9일 월요일, 오후 12:30 ET에 발표할 예정입니다.
발표 외에도, Celularity는 회의 동안 개별 투자자 미팅을 진행할 예정입니다. 관심 있는 분들은 H.C. Wainwright 대표나 KCSA Strategic Communications에 연락하여 미팅을 예약할 수 있습니다. 발표의 재생은 행사 후 최소 90일 동안 Celularity의 웹사이트에서 확인할 수 있습니다.
Celularity (Nasdaq: CELU), une entreprise de médecine régénérative et cellulaire, a annoncé sa participation à la 26e Conférence Annuelle Mondiale sur les Investissements de H.C. Wainwright. L'événement se déroulera au Lotte New York Palace Hotel du 9 au 11 septembre 2024. Robert J. Hariri, M.D., Ph.D., Président, CEO et fondateur de Celularity, est prévu pour faire une présentation le lundi 9 septembre 2024, à 12h30 ET.
En plus de la présentation, Celularity participera à des rencontres individuelles avec des investisseurs pendant la conférence. Les parties intéressées peuvent contacter les représentants de H.C. Wainwright ou KCSA Strategic Communications pour programmer des réunions. Un enregistrement de la présentation sera disponible sur le site web de Celularity pendant au moins 90 jours après l'événement.
Celularity (Nasdaq: CELU), ein Unternehmen für regenerative und zelluläre Medizin, gab seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright bekannt. Die Veranstaltung findet im Lotte New York Palace Hotel vom 9. bis 11. September 2024 statt. Robert J. Hariri, M.D., Ph.D., Vorsitzender, CEO und Gründer von Celularity, wird voraussichtlich am Montag, den 9. September 2024, um 12:30 Uhr ET präsentieren.
Zusätzlich zur Präsentation wird Celularity während der Konferenz an eins-zu-eins Investorenmeetings teilnehmen. Interessierte Parteien können H.C. Wainwright-Vertreter oder KCSA Strategic Communications kontaktieren, um Meetings zu vereinbaren. Eine Wiederholung der Präsentation wird für mindestens 90 Tage nach der Veranstaltung auf der Website von Celularity verfügbar sein.
- None.
- None.
FLORHAM PARK, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company developing placental-derived allogeneic cell therapies and advanced biomaterial products, today announced that Robert J. Hariri, M.D., Ph.D., Chairman, CEO and founder, will present at H.C. Wainwright’s 26th Annual Global Investment Conference being held at the Lotte New York Palace Hotel in New York City on September 9-11, 2024.
H.C. Wainwright 26th Annual Global Investment Conference
Date: Monday, September 9, 2024
Time: 12:30 p.m. ET
Location: Lotte New York Palace Hotel, New York
Speaker: Robert J. Hariri, M.D., Ph.D., Founder, Chairman & CEO
Celularity will also participate in one-on-one investor meetings at the conference. To obtain more information on the conference, or schedule an investor meeting with Dr. Hariri, please contact your H.C. Wainwright representative or KCSA Strategic Communications at Celularity@KCSA.com.
A replay of this presentation will be available on the Company's website at https://celularity.com/investor-relations/ for at least 90 days following the date of the presentation.
About Celularity
Celularity Inc. (NASDAQ: CELU) is an innovative regenerative and cellular medicine company. It is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. What sets Celularity apart is its therapeutic programs that target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells (MLASCs), T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Celularity’s unique approach, harnessing the placenta’s biology and ready availability, is paving the way for therapeutic solutions that address significant unmet global needs for effective, accessible, and affordable therapies.
Carlos Ramirez
Senior Vice President, Celularity Inc.
Carlos.ramirez@celularity.com
Raquel Cona / Michaela Fawcett
KCSA Strategic Communications
rcona@kcsa.com / mfawcett@kcsa.com
FAQ
When and where is Celularity (CELU) presenting at the H.C. Wainwright Global Investment Conference?
Who will be presenting for Celularity (CELU) at the H.C. Wainwright conference?
Will Celularity (CELU) be available for investor meetings at the H.C. Wainwright conference?
How long will the replay of Celularity's (CELU) presentation be available on their website?
